Bernales Sebastian bought MGX

February 13, 2024 · Form 4 insider transaction

Bernales Sebastian bought 1,896,445 shares of Metagenomi Therapeutics, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 1 day after the transaction.

Direction
Acquired (buy-side)
Shares
1,896,445
Price
N/A
Total value
N/A
RoleDirector
SecurityCommon Stock
Transaction codeC: Conversion of a derivative
Transaction dateFebruary 13, 2024
Filing dateFebruary 14, 2024
Shares owned after1,896,445
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

Upon closing of the Issuer's initial public offering, each share of Series A-2 Preferred Stock, Series A-3 Preferred Stock, Series A-4 Preferred Stock, Series B Preferred Stock, and Series B-1 Preferred Stock (collectively, the "Preferred Stock") automatically converted on a one-for-one basis into shares of the Issuer's Common Stock (on an adjusted basis, after giving effect to the reverse stock split of the Common Stock at a ratio of 1 to 1.74692 effected by the Issuer on January 26, 2024). The Preferred Stock had no expiration date.; Represents securities held directly by Humboldt Fund I, LP. Humboldt Fund I, LP is solely managed by Humboldt Capital, LLC, which is in turn managed by Sebastian Bernales, Francisco Dopazo and Benjamin Quiroga. Each of Mr. Bernales, Dopazo and Quiroga expressly disclaims beneficial ownership of the securities held by Humboldt Fund I, LP, except to the extent of his pecuniary interest in such securities.

View the original Form 4 on SEC EDGAR